{"denoms":[{"counts":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"191"},{"groupId":"BG002","value":"375"}],"units":"Participants"}],"groups":[{"description":"Participants received enzalutamide 160 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"BG000","title":"Enzalutamide"},{"description":"Participants received bicalutamide 50 mg orally once daily until confirmed radiographic disease progression, skeletal-related event or the initiation of a new antineoplastic therapy.","id":"BG001","title":"Bicalutamide"},{"description":"Total of all reporting groups","id":"BG002","title":"Total"}],"measures":[{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","spread":"9.22","value":"70.3"},{"groupId":"BG001","spread":"8.89","value":"71.1"},{"groupId":"BG002","spread":"9.05","value":"70.7"}]}]}],"dispersionType":"STANDARD_DEVIATION","paramType":"MEAN","title":"Age, Continuous","unitOfMeasure":"years"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"45"},{"groupId":"BG001","value":"47"},{"groupId":"BG002","value":"92"}]}],"title":"< 65 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"85"},{"groupId":"BG001","value":"80"},{"groupId":"BG002","value":"165"}]}],"title":"65-75 years"},{"categories":[{"measurements":[{"groupId":"BG000","value":"54"},{"groupId":"BG001","value":"64"},{"groupId":"BG002","value":"118"}]}],"title":"> 75 years"}],"paramType":"NUMBER","title":"Age, Customized","unitOfMeasure":"participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"0"},{"groupId":"BG002","value":"0"}],"title":"Female"},{"measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"191"},{"groupId":"BG002","value":"375"}],"title":"Male"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Sex: Female, Male","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"172"},{"groupId":"BG001","value":"176"},{"groupId":"BG002","value":"348"}]}],"title":"White"},{"categories":[{"measurements":[{"groupId":"BG000","value":"8"},{"groupId":"BG001","value":"10"},{"groupId":"BG002","value":"18"}]}],"title":"Black or African American"},{"categories":[{"measurements":[{"groupId":"BG000","value":"3"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"5"}]}],"title":"Asian"},{"categories":[{"measurements":[{"groupId":"BG000","value":"1"},{"groupId":"BG001","value":"1"},{"groupId":"BG002","value":"2"}]}],"title":"Native Hawaiian or Other Pacific Islander"},{"categories":[{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"2"},{"groupId":"BG002","value":"2"}]}],"title":"Other"}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Race/Ethnicity, Customized","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"184"},{"groupId":"BG001","value":"187"},{"groupId":"BG002","value":"371"}],"title":"Not Hispanic or Latino"},{"measurements":[{"groupId":"BG000","value":"0"},{"groupId":"BG001","value":"4"},{"groupId":"BG002","value":"4"}],"title":"Hispanic or Latino"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"Ethnicity","unitOfMeasure":"Participants"},{"classes":[{"categories":[{"measurements":[{"groupId":"BG000","value":"87"},{"groupId":"BG001","value":"76"},{"groupId":"BG002","value":"163"}],"title":"Before diagnosis of metastasis"},{"measurements":[{"groupId":"BG000","value":"97"},{"groupId":"BG001","value":"115"},{"groupId":"BG002","value":"212"}],"title":"After diagnosis of metastasis"}]}],"paramType":"COUNT_OF_PARTICIPANTS","title":"LHRH agonist/antagonist initiation or bilateral orchiectomy relative to diagnosis of metastasis","unitOfMeasure":"Participants"}],"populationDescription":"The baseline analysis population consisted of all participants that were randomized to receive study drug."}